Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM ... - MarketWatch (press release)
SunHerald.
Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM ... - EON: Enhanced Online News (press release)
Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM .
Long-term Injectable Drug Effective for Schizophrenia - Medscape
Long-term Injectable Drug Effective for SchizophreniaMedscapeMay 11, 2012 (Philadelphia, Pennsylvania) — Intramuscular depot aripiprazole is a safe and tolerable option for long-term maintenance treatment of schizophrenia, according to several presentations from a new large trial presented here at the American .
Treatment of refractory catatonic schizophrenia with low dose aripiprazole - 7thSpace Interactive (press release)
Treatment of refractory catatonic schizophrenia with low dose aripiprazole7thSpace Interactive (press release)However, treatment with low-dose aripiprazole dramatically improved the patient's psychotic symptoms and extrapyramidal symptoms.
Abilify Does Well in Depot Version - MedPage Today
Abilify Does Well in Depot VersionMedPage TodayNote that a phase III study was halted at a preplanned interim data point which demonstrated fewer relapses with depot aripiprazole compared with placebo for long-term maintenance in schizophrenia.